Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 37, showing 5 Applications out of 183 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s)

16.

ECCT/24/04/01   B/F/TAF to DTG/3TC Switch Stud
    Efficacy, Safety and Tolerability of Switching to DTG/3TC Single Tablet Regimen from B/F/TAF in Older Persons Living with HIV in Kenya   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Kenyatta National Hospital (Nairobi City county)
 
View

17.

ECCT/24/03/06   PHOENIx MDR-TB)
    Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)   
Principal Investigator(s)
1. Dr Lucy Chepkurui Koech KOECH
Site(s) in Kenya
1. Kenya medical Research Institute/ Walter Reed Project (Kericho county)
2. Moi university clinic research Centre (Uasin Gishu county)
 
View

18.

ECCT/24/03/04   MK8591A-053 Trial
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county)
2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county)
3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county)
 
View

19.

ECCT/24/03/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr. Janet Nyawira Oyieko
Site(s) in Kenya
1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
 
View

20.

ECCT/24/02/10   IMBrave
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA   
Principal Investigator(s)
1. Dr. Pauline Njoki Njiraini
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View